Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

While you're collecting healthy dividends, you'll also benefit from the price-to-earnings (P/E) ratio expanding when revenue ...

The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year.

Turning to Wall Street, the analysts’ consensus rating for Pfizer is Hold, based on five Buy, 11 Hold, and a single Sell ...

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Tilray Brands jumped 27.54% to close at $13.94, after trading between an intraday low of $10.50 and a high of $14.55; the ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

The drop reflects investors reactions to Pfizer’s new 2026 revenue forecasts, which is set to be between the range of $59.5 billion to $62.5 billion, a decline of $1.5 billion from 2025’s estimated ...

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.